辛伐他汀用于结直肠癌治疗的系统综述

doi:10.11904/j.issn.1002-3070.2021.04.013

Abstract

Abstract: “Drug reuse” or “drug relocation” is a hot topic in the field of oncology.It refers to finding a marketed drug with anticancer activity that is not a cancer indication,and combining it with conventional cancer treatments with a view to bringing survival benefits to patients.Simvastatin is commonly used clinically to treat hyperlipidemia and prevent cardiovascular diseases.Many studies have found that simvastatin has great potential for the treatment of colorectal cancer.Many clinical studies have tried to use simvastatin as an adjuvant drug for the treatment of metastatic colorectal cancer.

Key words: Colorectal cancer, Simvastatin, Drug reuse, Drug relocation

CLC Number:

R735.3

HUANG Rui, LIU Chao, ZHANG Yanqiao. A systematic review of simvastatin in the treatment of colorectal cancer[J]. Journal of Practical Oncology, 2021, 35(4): 365-369.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.04.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I4/365

References

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Langedijk J,Mantel-Teeuwisse AK,Slijkerman DS,et al.Drug repositioning and repurposing:terminology and definitions in literature[J].Drug Discovery Today,2015,20(8):1027-1034.
3 Cho SJ,Kim JS,Kim JM,et al.Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts,and attenuates colitis-associated colon cancer in mice[J].Int J Cancer,2008,123(4):951-957.
4 Liu Y,Tang W,Wang J,et al.Association between statin use and colorectal cancer risk:a meta-analysis of 42 studies[J].Cancer Causes Control,2014,25(2):237-249.
5 Karapetis CS,Khambata Ford S,Jonker DJ,et al.KRAS mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359(17):1757-1765.
6 Brandi G,Biasco G,Tavolari S.Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations[J].J Natl Cancer Inst,2011,103(16):1278.
7 Lee J,Lee I,Han B,et al.Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations[J].J Natl Cancer Inst,2011,103(8):674-688.
8 Jang HJ,Hong EM,Kim M,et al.Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2(Nrf2)activation through ERK and PI3K/Akt pathway in colon cancer[J].Oncotarget,2016,7(29):46219-46229.
9 Chen MJ,Cheng AC,Lee MF,et al.Simvastatin induces G1 arrest by up-regulating GSK3β and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells[J].J Cell Physiol,2018,233(6):4618-4625.
10 Zheng XF,Liu KX,Wang XM,et al.MicroRNA 192 acts as a tumor suppressor in colon cancer and simvastatin activates miR 192 to inhibit cancer cell growth[J].Mol Med Rep,2019,19(3):1753-1760.
11 Kajiho H,Kajiho Y,Frittoli E,et al.RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs[J].EMBO Rep,2016,17(7):1061-1080.
12 Rodriguez JA,Huerta-Yepez S,Law IK,et al.Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling[J].Cell Mol Gastroenterol Hepatol,2015,1(6):610-630.
13 Uwafuji S,Goi T,Naruse T,et al.Protein-bound polysaccharide K reduced the invasive ability of colon cancer cell lines[J].Anticancer Res,2013,33(11):4841-4845.
14 Bao H,Zhang Q,Zhu Z,et al.BHX,a novel pyrazoline derivative,inhibits breast cancer cell invasion by reversing the epithelial-mesenchymal transition and down-regulating Wnt/β-catenin signalling[J].Sci Rep,2017,7(1):9153.
15 Carmeliet P,Jain RK.Molecular mechanisms and clinical applications of angiogenesis[J].Nature,2011,473(7347):298-307.
16 Li G,Zheng J,Xu B,et al.Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer[J].Biomed Pharmacother,2017,85:418-424.
17 Karagkounis G,Devecchio J,Ferrandon S,et al.Simvastatin enhances radiation sensitivity of colorectal cancer cells[J].Surg Endosc,2018,32(3):1533-1539.
18 Lee MH,Cho YS,Han YM.Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation[J].Stem Cells,2010,25(7):1654-1663.
19 Zhang Z,Li S,Cui M,et al.Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways[J].Basic Res Cardiol,2013,108(2):333.
20 Kodach LL,Jacobs RJ,Voorneveld PW,et al.Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell′stemness′ via the bone morphogenetic protein pathway[J].Gut,2011,60(11):1544-1553.
21 Lim SH,Kim TW,Hong YS,et al.A randomised,double-blind,placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer[J].Br J Cancer,2015,113(10):1421-1426.
22 Weis M,Heeschen C,Glassford AJ,et al.Statins have biphasic effects on angiogenesis[J].Circulation,2002,105(6):739-745.
23 Lee SJ,Lee I,Lee J,et al.Statins,3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors,potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2,BiP and Hsp90alpha in human colorectal cancer[J].Br J Cancer,2014,111(3):497-505.
24 Kim Y,Kim TW,Han SW,et al.A single arm,phase II study of simvastatin plus XELOX and bevacizumab as first-line chemotherapy in metastatic colorectal cancer patients[J].Cancer Res Treat,2019,51(3):1128-1134.
25 Saltz LB,Clarke S,Diaz-Rubio E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study[J].J Clin Oncol,2008,26(12):2013-2019.
26 Krens LL,Simkens LHJ,Bass JM,et al.Statin use as not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients:results from the CAIRO2 study[J].PLoS One,2014,9(11):e112201.
27 Baas JM,Krens LL,Tije AJ,et al.Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients[J].Investigational New Drugs,2015,33(6):1242-1247.
28 Fransgaard T,Hallas J,Thygesen LC,et al.Association of statin use and oncological outcomes after neoadjuvant radiotherapy in patients with rectal cancer[J].Anticancer Res,2019,39(4):2177-2182.
29 Suh N,Reddy BS,DeCastro A,et al.Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats[J].Cancer Prev Res(Phila),2011,4(11):1895-1902.
30 Jung YS,Park CH,Eun CS,et al.Statin use and the risk of colorectal adenoma:A meta-analysis[J].J Gastroenterol Hepatol,2016,31(11):1823-1830.
31 Cheung KS,Chen L,Chan EW,et al.Statins reduce the progression of non-advanced adenomas to colorectal cancer:a postcolonoscopy study in 187 897 patients[J].Gut,2019,68(11):1979-1985.
32 Lochhead P,Chan AT.Statins and colorectal cancer[J].Clin Gastroenterol Hepatol,2013,11(2):109-118.
33 Ronac M,Lewis JD,Scott FI,et al.Disentangling the Association between statins,cholesterol,and colorectal cancer:a nested case-control study[J].PLoS Medicine,2016,13(4):e1002007.
34 van Duijnhoven FJ,Bueno-De-Mesquita HB,Calligaro M,et al.Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition[J].Gut,2011,60(8):1094-1102.
35 Law MR,Thompson SG.Low serum cholesterol and the risk of cancer:an analysis of the published prospective studies[J].Cancer Causes Control,1991,2(4):253-261.
36 Agarwal B,Bhendwal S,Halmos B,ei al.Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells[J].Clin Cancer Res,1999,5(8):2223-2229.
37 Scharping NE,Menk AV,Whetstone RD,et al.Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia[J].Cancer Immunol Res,2017,5(1):9-16.
38 Xie G,Cheng T,Lin J,et al.Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy[J].J Immunother Cancer,2018,6(1):88.
39 Oechsle CM,Showalter LE,Novak CM,et al.Statin drugs plus Th1 cytokines potentiate apoptosis and ras delocalization in human breast cancer lines and combine with dendritic cell-based immunotherapy to suppress tumor growth in a mouse model of HER-2pos disease[J].Vaccines(Basel),2020,8(1):72.

[1]	LIU Wen, QIAO Wenbo. Clinical research status of programmed cell death protein-1 and its ligand in colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(4): 370-375.
[2]	ZHU Gongjian, ZHU Yitong, DING Gaoheng, WANG Hongzong, DU Meixia, LIU Yuqin. Analysis for characteristics and trends of colorectal cancer in Gansu cancer registry areas,2009—2015 [J]. Journal of Practical Oncology, 2021, 35(3): 212-217.
[3]	GUO Piaoting, MIN Li, CHEN Jianjun, WANG Xin, NI Siyi. Salvianolic acid B regulates ROS to inhibit the proliferation and promote apoptosis in colorectal cancer HCT-116 cells [J]. Journal of Practical Oncology, 2020, 34(6): 504-510.
[4]	GUO Piaoting, ZOU Yang. LncRNA SOX2OT sponge adsorbs miR-34a to promote SOX2 expression and enhance multidrug resistance in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 398-403.
[5]	DONG Manku, JIANG Fuquan, LIN Haiguan, SUN Xiaomin, LIU Jingxin, HU Gang, YANG Jianwu. LncRNA BLACAT1 targeting LEMD1 promotes the proliferation and metastasis of colorectal cancer cells [J]. Journal of Practical Oncology, 2020, 34(5): 418-424.
[6]	SUN Xiaoyan, ZHANG Xiaoyan. Prognostic significance of lncRNA-SChLAP1 high-expression in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 425-429.
[7]	ZHAO Rencheng, LIN Zitang, YU Weijun, LEI Lin, LIU Zheng, XU Ying, GUO Yanfang, PENG Ji. Analysis of the prevalence of five cancer risks among permanent residents aged 40~74 years old in Baoan District,Shenzhen,2017—2019 [J]. Journal of Practical Oncology, 2020, 34(4): 315-320.
[8]	LI Hengzhen, ZHANG Yanqiao. Application progress of liquid biopsy in the diagnosis of colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(4): 357-361.
[9]	ZHU Xiaoyun,ZHANG Yaning,MA Biping. Trend analysis of the death level and the probability of early death caused by colorectal cancer in Jinshan district,Shanghai,1980—2018 [J]. Journal of Practical Oncology, 2020, 34(3): 198-202.
[10]	LU Xuemei,LI Yuntao,AN Jinhui,JI Guozhong. The mechanism of lysophosphatidic acid in the development of colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(3): 276-281.
[11]	LI Bin, FENG Baoheng, YIN Fuxia, SU Wei. Establishment of a colorectal cancer xenograft model to study the bacterial infection in the intestine of mice and the mechanism of decitabine combined with cisplatin chemotherapy [J]. Journal of Practical Oncology, 2020, 34(2): 163-168.
[12]	ZENG Li, ZHUANG Shutong, DING Shihua, CHEN Chong, JIAO Lu, SUN Dayong. Molecular mechanisms of long non-coding RNA AFAP1-AS1 regulating the proliferation of colorectal cancer cells by PTEN/p-AKT signaling pathway [J]. Journal of Practical Oncology, 2020, 34(1): 11-16.
[13]	LIAO Daixiang, ZHENG Bo, ZHANG Yanbin, YU Junhui. Expression of RRBP1 and RABEX-5 proteins in colorectal cancer and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(1): 43-48.
[14]	ZHANG Jinglan, LIU Ruibao. Progress in local interventional therapy for colorectal cancer with liver metastasis [J]. Journal of Practical Oncology, 2020, 34(1): 79-82.
[15]	LI Zhijie, ZHAO Qi, WU Huaxing. Research progress in the effects of intestinal microbes on colorectal cancer patients by metagenomics [J]. Journal of Practical Oncology, 2020, 34(1): 93-96.

A systematic review of simvastatin in the treatment of colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments